Mycenax Biotech Inc. (4726) was invited today to participate in the institutional investor conference hosted by National Securities to report its recent business achievements, commercial manufacturing progress, and future growth strategies. Chairman Pei-Jiun Chen stated that since transitioning into a 100% dedicated biologics CDMO in 2019, Mycenax has established a proven track record in the commercial manufacturing of two globally approved drugs, officially entering a new phase as a supplier for international commercialized pharmaceuticals.
Currently, these two commercial-stage drugs serve as a vital cornerstone for Mycenax's revenue growth, with products manufactured now supplying 13 international markets including Europe, Canada, and Japan. Concurrently, Mycenax's drug substance (DS) and sterile filling dual processes successfully passed inspections by six regulatory authorities within a single year. Notably, the company completed and passed audits from major regulatory agencies such as the European Medicines Agency (EMA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) within a three-month span, fully demonstrating its high-quality GMP manufacturing capabilities. As global commercial manufacturing continues to scale up, it will enhance capacity utilization and deliver increasingly significant revenue contributions to the company.
In terms of financial performance, Mycenax's Q1 2026 revenue reached NT$197 million, representing an increase of approximately NT$75 million (a 62% YoY growth) compared to the same period last year. Net loss after tax also narrowed by approximately NT$12 million year-on-year, reflecting continuous operational improvements. Cumulative revenue from January to April 2026 totaled approximately NT$304 million, a year-on-year surge of over 100%, indicating that the benefits of commercial-scale manufacturing are progressively materializing in overall revenue growth.
Looking ahead, in addition to the mass production of the two existing commercial drugs, Mycenax is steadily advancing several tech-transfer projects for commercialized products as well as late-stage clinical pipeline programs. The number of commercial-stage drugs in its portfolio is projected to increase from the current two to four or five within the next one to two years, positioning commercial products as the primary driver for mid-to-long-term revenue growth.
Regarding its strategic layout in the Japanese market, Mycenax has deeply cultivated Japan for 14 years, accumulating 30 collaborative clients and executing over 40 projects. In 2025, the number of Japanese clients grew by 140%. Furthermore, Mycenax has joint-ventured with its Japanese strategic partner to establish Alfenax Biologics, with plans to build a biologics production facility in Japan. Scheduled to become operational by 2030, this new site will double the company's overall production capacity, strengthen its stable supply capabilities, and foster closer proximity to the Japanese market and client demands.
Chairman Pei-Jiun Chen emphasized that Mycenax has successfully evolved from a clinical-stage CDMO into an international commercial pharmaceutical supplier. Moving forward, the company will continue to leverage international quality, stable mass production, and long-term partnerships as its core strengths. By driving more commercial product tech-transfers and late-stage clinical projects while deepening its footprint in the Japanese market, Mycenax is steadily advancing toward its goal of becoming a leading global biologics CDMO.
About Mycenax
Mycenax positions its Bio-CDMO brand around the core philosophy of "Big D, Strong M": Leveraging innovative development capabilities (D) and well-scalable manufacturing capacity (M), the company provides a fully integrated, one-stop shop for the development and manufacturing of both traditional and emerging biologics. Mycenax’s core value lies in its regulatory-compliant and highly market-competitive biologics development technologies and cGMP manufacturing facilities, seamlessly fulfilling the mission of bridging the gap between R&D achievements and pharmaceutical commercialization. With Taiwan as its central development and manufacturing hub, Mycenax integrates upstream and downstream industry chains to deliver comprehensive contract development and manufacturing services (CDMO).
Mycenax was established in September 2001, and current capital is NT$2.07 billion.
Stock Code: Mycenax (4726)
Official Website: http://www.mycenax.com
Press Contact:
Liru Yeh
Tel: +886-2-2655-8951 Ext. 6102
Email: liru.yeh@mycenax.com
Mycenax Biotech Inc. (4726) was invited today to participate in the institutional investor conference hosted by National Securities to report its recent business achievements, commercial manufacturing progress, and future growth strategies. Chairman Pei-Jiun Chen stated that since transitioning into a 100% dedicated biologics CDMO in 2019, Mycenax has established a proven track record in the commercial manufacturing of two globally approved drugs, officially entering a new phase as a supplier for international commercialized pharmaceuticals.
Currently, these two commercial-stage drugs serve as a vital cornerstone for Mycenax's revenue growth, with products manufactured now supplying 13 international markets including Europe, Canada, and Japan. Concurrently, Mycenax's drug substance (DS) and sterile filling dual processes successfully passed inspections by six regulatory authorities within a single year. Notably, the company completed and passed audits from major regulatory agencies such as the European Medicines Agency (EMA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) within a three-month span, fully demonstrating its high-quality GMP manufacturing capabilities. As global commercial manufacturing continues to scale up, it will enhance capacity utilization and deliver increasingly significant revenue contributions to the company.
In terms of financial performance, Mycenax's Q1 2026 revenue reached NT$197 million, representing an increase of approximately NT$75 million (a 62% YoY growth) compared to the same period last year. Net loss after tax also narrowed by approximately NT$12 million year-on-year, reflecting continuous operational improvements. Cumulative revenue from January to April 2026 totaled approximately NT$304 million, a year-on-year surge of over 100%, indicating that the benefits of commercial-scale manufacturing are progressively materializing in overall revenue growth.
Looking ahead, in addition to the mass production of the two existing commercial drugs, Mycenax is steadily advancing several tech-transfer projects for commercialized products as well as late-stage clinical pipeline programs. The number of commercial-stage drugs in its portfolio is projected to increase from the current two to four or five within the next one to two years, positioning commercial products as the primary driver for mid-to-long-term revenue growth.
Regarding its strategic layout in the Japanese market, Mycenax has deeply cultivated Japan for 14 years, accumulating 30 collaborative clients and executing over 40 projects. In 2025, the number of Japanese clients grew by 140%. Furthermore, Mycenax has joint-ventured with its Japanese strategic partner to establish Alfenax Biologics, with plans to build a biologics production facility in Japan. Scheduled to become operational by 2030, this new site will double the company's overall production capacity, strengthen its stable supply capabilities, and foster closer proximity to the Japanese market and client demands.
Chairman Pei-Jiun Chen emphasized that Mycenax has successfully evolved from a clinical-stage CDMO into an international commercial pharmaceutical supplier. Moving forward, the company will continue to leverage international quality, stable mass production, and long-term partnerships as its core strengths. By driving more commercial product tech-transfers and late-stage clinical projects while deepening its footprint in the Japanese market, Mycenax is steadily advancing toward its goal of becoming a leading global biologics CDMO.
About Mycenax
Mycenax positions its Bio-CDMO brand around the core philosophy of "Big D, Strong M": Leveraging innovative development capabilities (D) and well-scalable manufacturing capacity (M), the company provides a fully integrated, one-stop shop for the development and manufacturing of both traditional and emerging biologics. Mycenax’s core value lies in its regulatory-compliant and highly market-competitive biologics development technologies and cGMP manufacturing facilities, seamlessly fulfilling the mission of bridging the gap between R&D achievements and pharmaceutical commercialization. With Taiwan as its central development and manufacturing hub, Mycenax integrates upstream and downstream industry chains to deliver comprehensive contract development and manufacturing services (CDMO).
Mycenax was established in September 2001, and current capital is NT$2.07 billion.
Stock Code: Mycenax (4726)
Official Website: http://www.mycenax.com
Press Contact:
Liru Yeh
Tel: +886-2-2655-8951 Ext. 6102
Email: liru.yeh@mycenax.com
